Merck spinoff of organom

Can anyone tell me how Merck’s upcoming spinoff Organon will be treated by T212?
Will we get the shares or the value of the shares?
Personally I would prefer to get the shares.
Could @Team212 please clarify?

A post was merged into an existing topic: Demerger - process